Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
NCT07468903
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Adenocarcinoma
- Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Stage II Prostate Cancer AJCC v8
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Jonsson Comprehensive Cancer Center
- Last updated on ClinicalTrials.gov
- May 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.